Patient adherence to subcutaneous IFN beta-1a injections using the RebiSmart® injection device: a retrospective real-world study among Dutch and German patients with multiple sclerosis

Marieke Krol,1 Gert de Voer,2 Ulrike Osowski3 1QuintilesIMS, Capelle aan den Ijssel, the Netherlands; 2Merck B.V., Schiphol-Rijk, the Netherlands; 3Merck KGaA, Darmstadt, Germany Purpose: Long-term treatment adherence among patients with multiple sclerosis (MS) is a general concern, with an established correlation with clinical efficacy. Closely monitoring patients’ treatment behavior may have a beneficial effect on adherence. This study assessed adherence, in daily life, to subcutaneous (sc) IFN beta-1a, self-administered using the RebiSmart® electronic injection device (the IFN beta-Ia autoi... Mehr ...